Truist Securities upgraded Tandem Diabetes Care (NasdaqGM:TNDM) from Hold to Buy on March 19, 2026, with an analyst price forecast implying a 20.61% upside. The upgrade is a positive analyst signal that may lift the stock modestly (low-single-digit %s) on the news; monitor intraday flow and any accompanying target change for follow-through.
Truist Securities upgraded Tandem Diabetes Care (NasdaqGM:TNDM) from Hold to Buy on March 19, 2026, with an analyst price forecast implying a 20.61% upside. The upgrade is a positive analyst signal that may lift the stock modestly (low-single-digit %s) on the news; monitor intraday flow and any accompanying target change for follow-through.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
